BiotechTube

ABCL635 + Placebo

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vasomotor Symptoms Associated With Menopause

Conditions

Vasomotor Symptoms Associated With Menopause, Healthy Volunteers

Trial Timeline

Jun 23, 2025 → Feb 1, 2027

NCT ID
NCT07118891

About ABCL635 + Placebo

ABCL635 + Placebo is a phase 1/2 stage product being developed by AbCellera for Vasomotor Symptoms Associated With Menopause. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07118891. Target conditions include Vasomotor Symptoms Associated With Menopause, Healthy Volunteers.

What happened to similar drugs?

1 of 14 similar drugs in Vasomotor Symptoms Associated With Menopause were approved

Approved (1) Terminated (0) Active (13)
✅17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
🔄fezolinetant + placeboAstellas PharmaPhase 3
🔄DVS-233 SRPfizerPhase 3
🔄Bazedoxifene/Conjugated EstrogenPfizerPhase 3
🔄desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
🔄desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
🔄Elinzanetant (BAY3427080) + PlaceboBayerPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07118891Phase 1/2Recruiting

Competing Products

20 competing products in Vasomotor Symptoms Associated With Menopause

See all competitors
ProductCompanyStageHype Score
fezolinetant + placeboAstellas PharmaPhase 3
40
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiolEli LillyPhase 2
35
esomeprazole + placeboAstraZenecaPre-clinical
26
MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mgMerckPhase 2
27
Erenumab + PlaceboAmgenPhase 1
29
17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
43
DVS-233 SRPfizerPhase 3
40
Bazedoxifene/Conjugated EstrogenPfizerPhase 3
40
desvenlafaxine succinate sustained release (DVS SR)PfizerPhase 1
29
desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
40
desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
40
Treatment A + Treatment B + Treatment CBayerPhase 1
26
Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
26
Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
41
Elinzanetant (BAY3427080) treatment A + Elinzanetant (BAY3427080) treatment BBayerPhase 1
26
Elinzanetant (BAY3427080)BayerPhase 1
26
Moxifloxacin + Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
26
Elinzanetant (BAY3427080) + Dabigatran etexilateBayerPhase 1
26
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3
37
BAY3427080BayerPhase 1
26